FDA Webview Site FDA Review Site FDA Updater Site
header.gif
Username:
Password:
 

human drugs
animal drugs
biologics
eirs 483s
medical devices
marketing
email
search our site
  
FDA-RELATED NEWS
 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next >>
 
TXT Lexicon Refiling NDA for Sotagliflozin in Diabetes
03/12/2024
 
 
TXT $500 Million Boost to FDA in President’s Budget Proposal
03/11/2024
 
 
TXT Rinvoq Shows Promise in Arteritis: AbbVie
04/18/2024
 
 
TXT Data Show Long-Term Shingrix Efficacy: GSK
04/18/2024
 
 
TXT Philips Respironics Recalls Trilogy Evo Ventilators
04/18/2024
 
 
TXT FDA Approves Lumisight to Help Find Cancer
04/18/2024
 
 
TXT New PMI Form Explained
04/18/2024
 
 
TXT SCOTUS Won’t Hear False Labeling Case
04/18/2024
 
 
TXT Woodcock Plays Advisory Role at Patient Nonprofit
04/18/2024
 
 
TXT PhRMA Changes for Data Committee Guide
04/18/2024
 
 
TXT 3rd Eugia FDA-483 This Year So Far
04/17/2024
 
 
TXT It’s Official: Oncopeptides’ Pepaxto is Withdrawn
04/17/2024
 
 
TXT FDA Denies Generic Imodium Petition
04/17/2024
 
 
TXT FDA Reports on Device Safety, Innovation
04/17/2024
 
 
TXT Sen. Cassidy Challenges FDA on CDS Oversight
04/17/2024
 
 
TXT Lilly Filing NDA for Expanded Tirzepatide Use
04/17/2024
 
 
TXT Restrictions on Lutathera ANDA Sought
04/17/2024
 
 
TXT Sun Pharma Hit With 483 After India Inspection
04/17/2024
 
 
TXT Soulaire Marketing Unapproved Device: FDA
04/16/2024
 
 
TXT 2 CGMP Violations in Natco Pharma Inspection
04/16/2024
 
 
TXT Clinical Trial Innovation Center Established
04/16/2024
 
 
TXT Ex-CEO Sentenced Over Phony Covid Test
04/16/2024
 
 
TXT FDA Warns on Suspected Counterfeit Botox
04/16/2024
 
 
TXT Xstim Spine Fusion Stimulator Approved
04/16/2024
 
 
TXT CBER Joining Lupus Research Consortium
04/16/2024
 
 
TXT C&T Dream Co. CGMP Violations
04/16/2024
 
 
TXT New CDRH Dataset for Chemical Characterization
04/16/2024
 
 
TXT HeartMate Pumps Recalled Due to Obstructions
04/15/2024
 
 
TXT CDER Launches Trial Innovation Center
04/15/2024
 
 
TXT Clinical Hold on Neumora Study in Brain Diseases
04/15/2024
 
 
TXT Novartis Reports Favorable Data on Kidney Drug
04/15/2024
 
 
TXT FDA Inspection Hits Zydus With Form-483
04/15/2024
 
 
TXT Fresenius Recalls Infusion Pump Software
04/12/2024
 
 
TXT Sun Gets OAI Inspection at India Facility
04/12/2024
 
 
TXT Panel Backs Minimal Residual Disease Endpoint
04/12/2024
 
 
TXT Enlivex Mixed Results of Sepsis Cell Therapy
04/12/2024
 
 
TXT PureTech Gets Fast Track on LYT-200
04/12/2024
 
 
TXT AI Software Authorized for Osteoporosis Screens
04/12/2024
 
 
TXT EMA Committee Dismisses GLP-1 Suicidality Risk
04/12/2024
 
 
TXT FDA Updates Safety Labeling for Envarsus XR
04/12/2024
 
 
TXT Oncolytics Wants FDA Meeting on Pelareorep
04/11/2024
 
 
TXT 6 Observations in Cipla FDA-483
04/11/2024
 
 
TXT Roche Alzheimer’s Test is Breakthrough Device
04/11/2024
 
 
TXT Neurovalens Anxiety Device Cleared
04/11/2024
 
 
TXT Drug Shortages at Highest Level: ASHP
04/11/2024
 
 
TXT Califf Defends FDA Role in Patent Listings
04/11/2024
 
 
TXT Appeals Court Upholds Norwich ANDA Delay
04/11/2024
 
 
TXT 9 Applicants Chosen for Drug Quality Evaluation
04/11/2024
 
 
TXT FDA Complex Innovative Designs Meeting Praised
04/10/2024
 
 
TXT FDA OKs CAR-T Trial in Children for Lupus
04/10/2024
 
 
TXT Army Scientific Group’s Hemorrhage AI Detector Cleared
04/10/2024
 
 
TXT Italfarmaco Awarded Priority Review Voucher
04/10/2024
 
 
TXT Par Sues FDA Over BPI Epinephrine Approval
04/10/2024
 
 
TXT ODAC to Discuss Minimal Residual Disease Endpoint
04/10/2024
 
 
TXT Include Pregnant, Lactating Women in Trials: Report
04/10/2024
 
 
TXT Import Alert Against China Syringe Maker
04/10/2024
 
 
TXT Multiple Violations at Kilitch Healthcare India
04/09/2024
 
 
TXT CGMP Violations in Jiangsu Meifan Records Review
04/09/2024
 
 
TXT No Benefit in Many Cancer Accelerated Approvals
04/09/2024
 
 
TXT BrainStorm Gets FDA Buy-In on Special Protocol
04/09/2024
 
 
TXT Antaria API Deviations Cited
04/09/2024
 
 
TXT Vanda Case Could Produce Legislation: Report
04/09/2024
 
 
TXT 10 FDA Advisors Had Financial Ties with Abbott: KFF
04/09/2024
 
 
TXT Methodological Rigor Info May Help Promotions: OPDP
04/09/2024
 
 
TXT Alkem Labs Hit With 10-item Form-483
04/09/2024
 
 
TXT Philips Respironics Consent Decree Approved
04/09/2024
 
 
TXT ViiV Wins Adolescent HIV Use for Dovato
04/08/2024
 
 
TXT Spirair Nasal Septal Deviation Device Cleared
04/08/2024
 
 
TXT Carvykti Approved for Expanded Myeloma Use
04/08/2024
 
 
TXT FDA 2nd Complete Response on Parkinson’s Drug
04/08/2024
 
 
TXT De Novo for Antibacterial Coated Implants
04/08/2024
 
 
TXT Shuffert Debarred for 5 Years
04/05/2024
 
 
TXT Abecma Expanded Approval for Multiple Myeloma
04/05/2024
 
 
TXT Honeywell Recalls Eyewash Cartridge
04/05/2024
 
 
TXT Accelerated Approval for Enhertu in Solid Tumors
04/05/2024
 
 
TXT Jubilant Generics Cited Over GMPs
04/05/2024
 
 
TXT AbbVie Urges FDA to Ban Unlicensed Thyroid Products
04/05/2024
 
 
TXT Withdraw AvertD Approval: Scientists
04/04/2024
 
 
TXT 45 CDRH Safety Communications in 2022: Report
04/04/2024
 
 
TXT Medos Guide Sheath Recall is Class 1: FDA
04/04/2024
 
 
TXT Liquidia Expects FDA Yutrepia Final OK Soon
04/04/2024
 
 
TXT Novartis Seeking Expanded Pluvicto Label
04/04/2024
 
 
TXT FDA Cross-Center AI Paper Analyzed
04/04/2024
 
 
TXT Califf in Hot Seat at 4/11 Oversight Hearing
04/04/2024
 
 
TXT Amylyx Pulls ALS Drug From the Market
04/04/2024
 
 
TXT OPQ Supported 55 Novel Drug Approvals in 2023
04/03/2024
 
 
TXT Ignore Former FDAer’s Comments: Sidley
04/03/2024
 
 
TXT New Indication for Vanda’s Fanapt
04/03/2024
 
 
TXT Bipartisan Bill on Drug-Gene Interactions
04/03/2024
 
 
TXT Contract Pharma Cited on Environmental Issue
04/03/2024
 
 
TXT HHS Defines FDA Roles in Drug Shortages
04/03/2024
 
 
TXT Abbott's TriClip OK'd for Tricuspid Regurgitation
04/03/2024
 
 
TXT FDA Qualifies Lethal Arrhythmia Database
04/03/2024
 
 
TXT FDA OKs Zevtera Antibiotic with 3 Indications
04/03/2024
 
 
TXT Prenosis AI Sepsis Predictor Authorized for Use
04/03/2024
 
 
TXT More Changes Urged in RRA Revised Guidance Comments
04/02/2024
 
 
TXT CGMP Violations at Mexico’s Betone SA de CV
04/02/2024
 
 
TXT Multiple Agena Bioscience Violations
04/02/2024
 
 
TXT QS Issues in Beckman Coulter Inspection
04/02/2024
 
 
TXT 20 Safety Potential Signals in 4th Quarter 2023
04/02/2024
 
 
  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  Next >>
 
The most authoritative FDA news analysis each week is found in the pages of Dickinson's FDA Review. Since 1984, this newsletter has been providing in-depth reports on the most significant FDA developments affecting the pharmaceutical, medical device, biologics and veterinary medicines industries. Unlike other media, FDA Review eliminates time-wasting minutia and presents in clear, concise language the essence of what's really important - and why. It is the publication that FDA officials themselves read. Delivered in the middle of each week, FDA Review presents:
  • The latest agency policy developments, often before they're officially announced;
  • Major news insights, follow-ups and reactions in each product area;
  • Summaries of the latest Warning Letters;
  • The newest product approvals;
  • Summaries of the latest FDA Federal Register notices;
  • Summaries of DDMAC letters;
  • Related industry news capsules;
  • The industry's most concise FDA news index;
  • Inside-FDA news briefs
You can rely on FDA Review to provide only what's important - in the most convenient and time-saving